Literature DB >> 12803577

Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations.

Jue Quin Yang1, Sandrine Morin, Céline Verstuyft, Li An Fan, Yong Zhang, Chun Di Xu, Véronique Barbu, C Funck-Brentano, Patrice Jaillon, Laurent Becquemont.   

Abstract

Cytochrome P450 2C9 (CYP2C9) is a polymorphic enzyme responsible for the metabolism of different drugs with low therapeutic index such as oral anticoagulants. CYP2C9*2 and CYP2C9*3 are two single nucleotide polymorphic allelic variants. The frequency of these alleles in different ethnic populations is extremely variable. In this study, we compared the frequencies of CYP2C9 allelic variants among 394 Chinese living in Shanghai to 151 French Caucasians living in Paris. The allelic frequencies of CYP2C9 variants of the Chinese and the French subjects were 0.963, 0.001, 0.036 and 0.77, 0.15, 0.08 for CYP2C9*1, CYP2C9*2, CYP2C9*3, respectively. Chinese CYP2C9*3 allelic frequency was twice as lower as the French subjects, but three times higher than Korean (0.036 vs. 0.011). The CYP2C9*2 allele could be detected in only one Chinese subject, whereas it represented the major allelic variant in French Caucasians. The low frequency of the CYP2C9*2 and CYP2C9*3 allelic variants in Chinese subjects does not justify their detection in clinical practice, unlike French Caucasians.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12803577     DOI: 10.1046/j.1472-8206.2003.00148.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  20 in total

1.  Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

Authors:  Rania Abdelhedi; Nouha Abdelmoula Bouayed; Suad Alfadhli; Leila Abid; Ahmed Rebai; Najla Kharrat
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

2.  Allele and genotype frequencies of CYP2C9 in a Korean population.

Authors:  Jung-Woo Bae; Hyun-Kyung Kim; Ji-Hong Kim; Sang-In Yang; Mi-Jeong Kim; Choon-Gon Jang; Young-Seo Park; Seok-Yong Lee
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

3.  Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.

Authors:  Jung-woo Bae; Chang-ik Choi; Mi-jeong Kim; Da-hee Oh; Seul-ki Keum; Jung-in Park; Bo-hye Kim; Hye-kyoung Bang; Sung-gon Oh; Byung-sung Kang; Hyun-joo Park; Hae-deun Kim; Ji-hey Ha; Hee-jung Shin; Young-hoon Kim; Han-sung Na; Myeon-woo Chung; Choon-gon Jang; Seok-yong Lee
Journal:  Acta Pharmacol Sin       Date:  2011-08-15       Impact factor: 6.150

Review 4.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China.

Authors:  Qian Ren; Xueyao Han; Yong Tang; Xiuying Zhang; Xiantong Zou; Xiaoling Cai; Simin Zhang; Lihua Zhang; Hechao Li; Linong Ji
Journal:  Diabetologia       Date:  2013-12-20       Impact factor: 10.122

6.  Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.

Authors:  Ramasamy Kesavan; Sunil K Narayan; Chandrasekaran Adithan
Journal:  Eur J Clin Pharmacol       Date:  2010-07       Impact factor: 2.953

Review 7.  Implementing genotype-guided antithrombotic therapy.

Authors:  Richard L Seip; Jorge Duconge; Gualberto Ruaño
Journal:  Future Cardiol       Date:  2010-05

8.  Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.

Authors:  Ekta Varshney; Nilanjan Saha; Monika Tandon; Vikesh Shrivastava; Shakir Ali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-02-28       Impact factor: 2.441

9.  Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.

Authors:  Dechun Jiang; Xiangrong Bai; Qingxia Zhang; Wei Lu; Yuqin Wang; Lin Li; Markus Müller
Journal:  Eur J Clin Pharmacol       Date:  2009-09-16       Impact factor: 2.953

Review 10.  Pharmacogenetics of glucose-lowering drug treatment: a systematic review.

Authors:  Ozlem Bozkurt; Anthonius de Boer; Diederick E Grobbee; Eibert R Heerdink; Huib Burger; Olaf H Klungel
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.